check_circleStudy Completed

Contraception, Heavy menstrual bleeding (HMB)

Qlaira: Inhib. of CYP3A4 by ketoconazole a. erythrom

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 75 Years
  • -

  • -

Trial summary

Enrollment Goal
24
Trial Dates
April 2006 - July 2006
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Natazia/Qlaira (EV/DNG, BAY86-5027)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Pharma AGBerlin, 13353, Germany

Trial design

Open-label, two-group, one-sequence, one-way crossover study to evaluate the effect of ketoconazole and erythromycin on the steady-state pharmacokinetics of SH T00658M (2 mg estradiol valerate and 3 mg dienogest) in healthy postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A